PharmChem (PharmChem) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2023)

View and export this data going back to 2003. Start your Free Trial

What is PharmChem LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PharmChem's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.00.

PharmChem's long-term debt to total assets ratio declined from Mar. 2003 (0.03) to Sep. 2023 (0.00). It may suggest that PharmChem is progressively becoming less dependent on debt to grow their business.

PharmChem LT-Debt-to-Total-Asset Historical Data

The historical data trend for PharmChem's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmChem LT-Debt-to-Total-Asset Chart

PharmChem Annual Data

Trend

Dec93

Dec94

Dec95

Dec96

Dec97

Dec98

Dec99

Dec00

Dec01

Dec02

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.10

0.06

0.11

0.04

PharmChem Quarterly Data
	Jun99	Sep99	Dec99	Mar00	Jun00	Sep00	Dec00	Mar01	Jun01	Sep01	Dec01	Mar02	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Sep22	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.18	0.19	-	-

PharmChem LT-Debt-to-Total-Asset Calculation

PharmChem's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2002 is calculated as

LT Debt to Total Assets (A: Dec. 2002 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2002 )	/	Total Assets (A: Dec. 2002 )
	=	0.814	/	22.667
	=	0.04

PharmChem's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	0	/	3.252
	=	0.00

PharmChem (OTCPK:PCHM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PharmChem LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of PharmChem's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmChem (PharmChem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PharmChem Inc (OTCPK:PCHM) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2411 E. Loop 820 N, Fort Worth, TX, USA, 76118

Website

https://www.pharmchek.com

PharmChem Inc is engaged in selling and distributing of the PharmChek Sweat Patch Device. PharmChek is a system that uses sweat to detect the presence of illegal drugs. It consists of a transparent polyurethane outer covering, a small absorbent pad, and a release liner. Geographically the activities are carried out throughout the United States.

Executives

Alto Investors Palo	10 percent owner	470 UNIVERSITY AVENUE, PALO ALTO CA 94301
Micro Cap Partners Lp	10 percent owner

PharmChem (PharmChem) Headlines

From GuruFocus

PharmChem (PCHM) Announces Response To Opposition

By PRNewswire PRNewswire • 08-11-2021